Vital Images, Inc. a Minneapolis-based advanced medical imaging and informatics company, will feature its enterprise interoperability solutions at the HIMSS Asia Pacific annual conference in booth 412, 23-26 August in Bangkok, Thailand.
Momenta Pharmaceuticals, Inc , a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the Company has discontinued further accrual in its Phase 2 trial evaluating necuparanib in combination with Abraxane® and gemcitabine in patients with advanced metastatic pancreatic cancer.
Biogen announced that Bioverativ will be the name of the standalone, publicly-traded global biotechnology company that it expects to launch in early 2017. Bioverativ will be focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders. Following completion of the spin-off, Bioverativ plans to trade under the symbol BIVV on the NASDAQ Stock Market.